Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
暂无分享,去创建一个
Jorge Cortes | Guillermo Garcia-Manero | Francis J Giles | J. Issa | Rajan Mannari | H. Kantarjian | G. Garcia-Manero | J. Cortes | F. Giles | C. Rosenfeld | S. Faderl | J. Lyons | Hagop M Kantarjian | Stefan Faderl | Jean-Pierre J Issa | Deborah Thomas | Craig S Rosenfeld | Rajan Mannari | Emel Bayar | John Lyons | E. Bayar | D. Thomas
[1] J. Herman,et al. DNA methylation changes in hematologic malignancies: biologic and clinical implications. , 1997, Leukemia.
[2] J. Christman,et al. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy , 2002, Oncogene.
[3] P. Laird,et al. MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.
[4] J. Issa,et al. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] M. Toyota,et al. Methylated CpG island amplification for methylation analysis and cloning differentially methylated sequences. , 2002, Methods in molecular biology.
[6] E. Estey,et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia , 1997, Leukemia.
[7] Peter A. Jones,et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. , 2002, Blood.
[8] H. Kantarjian,et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. , 2002, Blood.
[9] T. Kinoshita,et al. Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes , 2000, Leukemia.
[10] S. Clark,et al. DNA methylation changes in leukaemia. , 2002, Seminars in cancer biology.
[11] Molecular pathogenesis of lung cancer. , 2002 .
[12] J. Issa,et al. Critical Role of Histone Methylation in Tumor Suppressor Gene Silencing in Colorectal Cancer , 2003, Molecular and Cellular Biology.
[13] M. Toyota,et al. Methylation profiling in acute myeloid leukemia. , 2001, Blood.
[14] R. Hoffman,et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. , 2000, Blood.
[15] Peter A. Jones,et al. The Role of DNA Methylation in Mammalian Epigenetics , 2001, Science.
[16] D. Zaharko,et al. Experimental chemotherapy (L1210) with 5-aza-2'-deoxycytidine in combination with pyran copolymer (MVE-4), an immune adjuvant. , 1985, Journal of the National Cancer Institute.
[17] J. Herman,et al. CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[18] N. Ahuja,et al. Methylation and silencing of the Thrombospondin-1 promoter in human cancer , 1999, Oncogene.
[19] J. Herman,et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.
[20] Peter A. Jones,et al. Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.
[21] S. Clark,et al. High sensitivity mapping of methylated cytosines. , 1994, Nucleic acids research.
[22] L. Zwelling,et al. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia , 1993 .
[23] Peter A. Jones,et al. Cancer-epigenetics comes of age , 1999, Nature Genetics.
[24] J. Issa,et al. Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications , 2001, Annals of Internal Medicine.
[25] M. Szyf,et al. DNA Methyltransferase Inhibition Induces the Transcription of the Tumor Suppressor p21 WAF1/CIP1/sdi1 * , 2000, The Journal of Biological Chemistry.
[26] Terry L. Smith,et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] P. Jones,et al. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. , 1998, Cancer research.
[28] J. Herman,et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[29] E. Amento,et al. Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. , 1993, The Journal of clinical investigation.
[30] M. Lübbert,et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] David A Jones,et al. Reactivating the expression of methylation silenced genes in human cancer , 2002, Oncogene.
[32] D. Lavelle,et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. , 2002, Blood.